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OBJECTIVES To determine the effects of furosemide and the selective A1 adenosine receptor BG9719 on
renal function in patients with congestive heart failure (CHF).
BACKGROUND Studies suggest that adenosine may affect renal function by various mechanisms, but the
effects of blockade of this system in humans is unknown. In addition, the effects of a
therapeutic dose of furosemide on glomerular filtration rate (GFR) and renal plasma flow
(RPF) in heart failure patients are controversial.
METHODS On different days, 12 patients received placebo, BG9719 and furosemide. Glomerular
filtration rate, RPF and sodium and water excretion were assessed immediately following drug
administration.
RESULTS Glomerular filtration rate was 84 6 23 ml/min/1.73m2 after receiving placebo, 82 6 24
following BG9719 administration and a decreased (p , 0.005) 63 6 18 following
furosemide. Renal plasma flow was unchanged at 293 6 124 ml/min/1.73m2 on placebo,
334 6 155 after receiving BG9719 and 374 6 231 after receiving furosemide. Sodium
excretion increased from 8 6 8 mEq following placebo administration to 37 6 26 mEq
following BG9719 administration. In the six patients in whom it was measured, sodium
excretion was 104 6 78 mEq following furosemide administration.
CONCLUSIONS Natriuresis is effectively induced by both furosemide and the adenosine A1 antagonist
BG9719 in patients with CHF. Doses of the two drugs used in this study did not cause
equivalent sodium and water excretion but only furosemide decreased GFR. These data
suggest that adenosine is an important determinant of renal function in patients with heart
failure. (J Am Coll Cardiol 2000;35:56–9) © 1999 by the American College of Cardiology
The impact of a diuretic on glomerular filtration rate (GFR)
is dependent both upon direct nephron effects and indirect
consequences of volume depletion. Not surprisingly, varying
the dose of a diuretic, the model studied or using drugs with
different efficacy or mechanism of action lead to conflicting
conclusions about the renal effects of diuretics. In patients
with congestive heart failure (CHF), a group likely to
experience adverse renal effects with a diuretic, even the
impact of a therapeutic dose of furosemide on GFR is
controversial.
Selective A1 adenosine receptor blockade could theoret-
ically cause diuresis by a novel mechanism that minimizes
the renal effects of volume depletion. The direct renal
actions of adenosine include reduced glomerular filtration,
perhaps by dilation of postglomerular vessels (1) or by
vasoconstrictive effects (2). Similar effects have been seen
when intravenous adenosine is given (3). Conversely, selec-
tive A1 receptor blockade has been shown to decrease
afferent arteriole pressure and increase urine flow and
sodium excretion (4). With these actions, it is possible that
an adenosine antagonist may both be able to cause diuresis
and maintain or improve glomerular filtration.
We therefore evaluated in a randomized, double-blind,
crossover trial, the effects of the selective A1 antagonist
BG9719 on GFR, renal plasma flow (RPF) and sodium and
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water excretion in patients with CHF. In addition, we
investigated the renal effects of open label furosemide in
patients with CHF.
METHODS
Patient population. We studied the renal response to
furosemide, BG9719 and placebo in 12 male patients with
CHF ages 42 to 73 years (mean 59 6 11). Nine patients
were classified as New York Heart Association functional
class III and three patients as class IV but all were clinically
stable and receiving constant daily doses of digoxin (mean
dose 0.21 6 0.06 mg), furosemide (66 6 58 mg) and
lisinopril (26 6 16 mg). The lisinopril dose was stable for at
least six weeks before the study. Patients were not hyper-
tensive or orthostatic. Baseline serum creatinine was ,2.5
mg/dL and baseline serum sodium was greater than
131 mEq/L. One patient was receiving beta-adrenergic
blocking agents and one patient was receiving spironolac-
tone. Patients abstained from xanthine or chocolate con-
taining foods for three days before the first dosing day and
during study participation. Patients refrained from solid
food for at least 10 h before initiation of the study drug. All
medications were given as prescribed except on the dosing
days of study when they were held until after renal function
assessment.
Study protocol. After written informed consent was ob-
tained, patients were admitted to a clinical research unit,
where they were stabilized for at least three days on a 30
mEq sodium, 60 mEq potassium and 1 to 1.5 g/kg protein
diet and no diuretics. When the patient’s weight did not
change by more than 1 kg on two sequential days, the
patient was randomized in a double blind manner to receive
either study drug (1 mg/kg of BG9719) or placebo (dosing
day 1). Drug was administered over 60 min. Renal plasma
flow and GFR were determined as were 2 h electrolyte and
water excretion.
Patients were then again stabilized on the same diet.
When weight did not change .1 kg for two consecutive
days and at least 72 h after dosing day 1, patients were
restudied. The protocol was the same as on dosing day 1,
except that patients received placebo if BG9719 was previ-
ously given or BG9719 if placebo was previously adminis-
tered.
At least two days after the second dosing day, the patient
received an intravenous dose of furosemide, equal to the
patient’s usual daily oral dose. For the one patient who was
not receiving a daily dose of furosemide, 40 mg was given.
The dose of furosemide given ranged from 20 to 200 mg
(mean 63 6 49 mg). Glomerular filtration rate and RPF
were then assessed. Glomerular filtration rate was not
obtained in one patient because of technical problems. On
the furosemide dosing day, sodium and water excretion were
measured for 2 h in six of the 12 patients.
Measurements of renal hemodynamics. Renal plasma
flow was measured by assessing the disappearance from the
serum of 60 mCi of 131I-orthodihippurate at precisely
44 min after the injection, as described by Tauxe and
colleagues (5). Glomerular filtration rate was determined by
the serum disappearance of 99mTc DTPA (6). 99mTc DTPA
was injected 1 h before study drug administration and blood
samples collected 0, 1 and 2 h after injection. 131I-hippuran
was injected at the same time as study drug administration
and RPF determined 0 to 44 min after isotope injection.
Data analysis. Renal hemodynamic response was assessed
by comparing differences obtained after placebo, BG9719
and furosemide administration. The differences were eval-
uated for normality with the Shapiro-Wilk test. A paired t
test was used to evaluate whether differences deviated
significantly from zero. All tests were two sided. P values
,0.05 without adjustment for multiple comparison were
considered statistically significant.
RESULTS
Renal hemodynamic response to therapy. The mean
GFR was 84 6 23 ml/min/1.73m2 for the 2 h after
receiving placebo, 82 6 24 ml/min/1.73m2 after BG9719
administration and 63 6 18 ml/min/1.73m2 after furo-
semide (Fig. 1). The difference between furosemide and
Abbreviations and Acronyms
CHF 5 congestive heart failure
GFR 5 glomerular filtration rate
RPF 5 renal plasma flow
Figure 1. The GFR for 11 patients following administration of
placebo, furosemide and BG9719. The mean GFR was 63 6 18
ml/min/1.73m2 following furosemide, 84 6 23 after receiving
placebo and 82 6 24 ml/min/1.73m2 following BG9719 admin-
istration. The difference between furosemide and both placebo and
BG9719 was significant, p , 0.005. GFR 5 glomerular filtration
rate.
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both placebo and BG9719 was significant, p , 0.005. Ten
of 11 patients showed a decline in GFR after furosemide.
The mean RPF was 293 6 124 ml/min/1.73m2 on
placebo, 334 6 155 ml/min/1.73m2 after receiving BG9719
and 374 6 231 ml/min/1.73m2 after receiving furosemide
(Fig. 2). None of the differences were statistically signifi-
cant.
Sodium excretion. The mean sodium excretion increased
from 8 6 8 mEq in the 2 h following placebo administra-
tion to 37 6 26 mEq in the 2 h following BG9719
administration (Fig. 3, p , 0.005). In the six patients in
whom it was measured, sodium excretion was 104 6
78 mEq in the 2 h following furosemide administration,
increasing markedly in one patient. This was significant as
compared with placebo (p , 0.05) but not as compared with
BG9719.
Urine volume. Similarly, urine volume increased from
156 6 107 ml after placebo to 501 6 293 ml for the 2 h
following BG9719 (p , 0.0005). Following furosemide
administration, urine volume was 1,080 6 529 ml (p ,
0.0005 vs. placebo and p , 0.006 vs. BG9719).
DISCUSSION
This study demonstrated that the adenosine A1 antagonist
BG9719 causes sodium and water excretion in patients with
CHF while maintaining GFR. Doses of furosemide that
caused even more diuresis produced clear evidence of
decreased renal function in patients with CHF.
Furosemide. The effect of furosemide on GFR has been
controversial. One study of seven healthy humans on salt
restricted diets demonstrated increased GFR (7), and high
dose furosemide increased GFR in a study of rats (8). On
the other hand, other animal (9–11) and human (12) studies
have demonstrated diuretic induced decreased GFR. The
marked findings of this study clearly show that diuresis with
furosemide in patients with CHF decreases glomerular
filtration.
Many mechanisms of action of furosemide might affect
GFR. Intravascular depletion might cause neurohormonal
activation, leading to decreased perfusion pressure by affer-
ent arteriolar constriction, efferent arteriolar dilation or
effects on renal blood flow. This study does not support
RPF as the cause of the marked decrease in renal function
caused by furosemide. On the other hand, the effects of
furosemide might be secondary to direct renal actions.
Indeed, bumetanide, another loop diuretic, appears to in-
duce a biphasic renal response, unrelated to diuresis (13).
This suggests that the effects of loop diuretics on prosta-
glandin E2 (14), the renin-angiotensin system, adenosine
receptors and tubuloglomerular feedback (15) might be
important.
BG9719. The importance of adenosine on renal function is
just beginning to be explored. Adenosine could be the
mechanism of some of the adverse effects of diuretics and
some of the decreased renal function seen in patients with
heart failure. However, the impact of adenosine adminis-
tration in people is not clear. While it appears to decrease
glomerular filtration, studies report divergent actions.
Adenosine decreased renal blood flow by a microvascular
vasoconstrictive effect in one study (2), but in nine patients
with CHF, adenosine increased renal vascular resistance and
decreased both blood flow in and cross section of the renal
artery (16). Postglomerular vascular dilation has also been
reported (1).
Selective adenosine A1 antagonists have similarly pro-
duced inconsistent renal effects. A1 antagonists increased
urine flow rate but caused no effect on renal blood flow in
normal human subjects (17) and dogs (18). However,
decreases in renal function caused by radiocontrast media
Figure 2. The renal plasma flow for each patient following
administration of placebo, furosemide and BG9719. There were
no significant differences among the groups.
Figure 3. The sodium excretion for each patient for the 2 h
following administration of placebo, furosemide and BG9719.
Sodium excretion increased with both BG9719 (p , 0.005) and
furosemide (p , 0.05).
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and cisplatin were attenuated by the adenosine antagonist
KW-3902 (19,20).
Some of the varying effects of adenosine and adenosine
antagonists might be related to the characteristics of the
subjects studied. For example, plasma adenosine levels are
increased in patients with CHF (21), and the renal effects in
this patient population might be different than in normal
subjects or in those with renal dysfunction caused by toxins.
The findings of this study suggest that BG9719 can cause
increased sodium excretion in patients with heart failure
without decreasing GFR. This suggests that adenosine may be
an important modulator of renal function in CHF patients.
Study limitations. While furosemide clearly decreased
GFR and BG9719 did not, the comparison is limited by the
different extent of natriuresis caused by the administered
doses of the two agents. Future comparisons should attempt
to compare doses that produce equally effective sodium and
urine volume excretion.
Urine was not collected by urethral catheters, which could
introduce bias because of incomplete collection. Slight
differences in sodium excretion and urine volume might
result. This study did not have the power to detect small
differences in RPF. However, the marked decrease of GFR
following furosemide without alteration in RPF to a similar
extent suggests that the effect on glomerular filtration is
caused by local renal actions rather than by changes in
delivery of blood to the kidneys.
This study analyzed patients with CHF. The conclusions
should not be extended to other patients, as the renal status of
heart failure patients is probably affected both by neurohor-
monal factors not seen in other subjects and by medications.
Conclusions. Natriuresis is effectively induced by both
furosemide and the adenosine A1 antagonist BG9719 in
patients with CHF. The doses of the two drugs used in this
study did not cause equivalent sodium and water excretion
but only furosemide caused a 25% decrease in GFR. If
BG9719 causes a similar maintenance of GFR when used
either at higher doses or in combination with other drugs
which produce greater diuresis, it would suggest that acti-
vation of adenosine A1 receptors is an important determi-
nant of renal function in diuresed patients with heart failure.
Adenosine A1 receptors have the potential to be clinically
useful in the many patients with heart failure who demon-
strate decreased renal function with diuresis.
Reprint requests and correspondence: Dr. Stephen S. Gottlieb,
Division of Cardiology, University of Maryland School of Medi-
cine, 22 South Greene Street, Baltimore, Maryland 21201. E-
mail: sgottlie@medicine.umaryland.edu.
REFERENCES
1. Edlund A, Ohlsen H, Sollevi A. Renal effects of local infusion of
adenosine in man. Clin Sci 1994;87:143–9.
2. Marraccini P, Fedele S, Marzilli, et al. Adenosine-induced renal
vasoconstriction in man. Cardiovasc Res 1996;32:949–53.
3. Balakrishnan VS, Coles GA, Williams JD. Effects of intravenous
adenosine on renal function in healthy human subjects. Am J Physiol
1996;40:F374–81.
4. Munger KA, Jackson EK. Effects of selective A1 receptor blockade on
glomerular hemodynamics: involvement of renin-angiotensin system.
Am J Physiol 1994;36:F783–90.
5. Tauxe WN, Dubovsky EV, Kidd T, Jr, Diaz F, Smith LR. New
formulas for the calculation of effective renal plasma flow. Eur J Nucl
Med 1982;7:51–4.
6. LaFrance ND, Drew HH, Walser M. Radioisotope measurement of
glomerular filtration rate in severe chronic renal failure. J Nucl Med
1988;29:1927–30.
7. Beutler JJ, Boer WH, Koomans HA, Dorhout Mees EJ. Renal
hemodynamic and tubular response to furosemide in man during
normal and restricted sodium intake. Nephron 1990;54:208–13.
8. Scherzer P, Wald H, Popovtzer MM. Enhanced glomerular filtration
rate and Na1-K1-ATPase with furosemide administration. Am J
Physiol 1987;252:F910–5.
9. Tenstad O, Williamson HE. Effect of furosemide on local and zonal
glomerular filtration rate in the rat kidney. Acta Physiol Scand
1995;155:99–107.
10. Lunau HE, Bak M, Peterson JS, Shalmi M, Marcussen N, Chris-
tensen S. Renal adaptations to continuous administration of furo-
semide and bendroflumethiazide in rats. Pharmacol Toxicol 1994;74:
216–22.
11. Smith FG, Abraham J. Renal and renin responses to furosemide in
conscious lambs during postnatal maturation. Can J Physiol Pharmacol
1995;73:107–12.
12. Skott P, Hommel E, Bruun NE, Arnold-Larsen S, Parving H-H. The
acute effect of acetazolamide on glomerular filtration rate and proximal
tubular reabsorption of sodium and water in normal man. Scand J Clin
Lab Invest 1989;49:583–7.
13. Bollerup AC, Hesse B, Sigurd B. Changes of glomerular filtration rate
and renal plasma flow following intravenous bumetanide in organic
heart disease. Acta Pharmacol Toxicol 1974;34:305–11.
14. Mackay IG, Muir AL, Watson ML. Contribution of prostaglandins to
the systemic and renal vascular response to frusemide in normal man.
Br J Clin Pharmacol 1984;17:513–9.
15. Okusa MD, Persson AE, Wright FS. Chlorothiazide effect on
feedback-mediated control of glomerular filtration rate. Am J Physiol
1989;257:F137–44.
16. Elkayam U, Mehra A, Cohen G, et al. Renal circulatory effects of
adenosine in patients with chronic heart failure. J Am Coll Cardiol
1998;32:211–5.
17. Balakrishnan VS, Coles GA, Williams JD. A potential role for
endogenous adenosine in control of human glomerular and tubular
function. Am J Physiol 1993;265:F504–10.
18. Yamagata T, Kobayahi T, Kusaka H, Karasawa A. Diuretic effects of
KW-3902, a novel adenosine A1-receptor antagonist in anesthetized
dogs. Biol Pharm Bull 1994;17:1599–603.
19. Arakawa K, Suzuki H, Naitoh M, et al. Role of adenosine in the renal
responses to contrast medium. Kidney Int 1996;49:1199–1206.
20. Nagashima K, Kusaka H, Karasawa A. Protective effects of KW-3902,
an adenosine A1-receptor antagonist, against cisplatin-induced acute
renal failure in rats. Jpn J Pharmacol 1995;67:349–57.
21. Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Hori
M. Plasma adenosine levels increase in patients with chronic heart
failure. Circulation 1997;95:1363–5.
59JACC Vol. 35, No. 1, 2000 Gottlieb et al.
January 2000:56–9 Renal Effects of Adenosine Antagonist and Furosemide
